复发性卵巢癌患者两种托泊替康治疗方案分析

方案A：托泊替康1.5mg/m2/d，d1-5/21d

方案B：托泊替康4.0mg/m2/d，d1,8,15/28d

二线治疗有效率：方案A和B分别为45%（9/20）和23.5%（4/17）

三线治疗有效率：方案A和B一共仅11%（3/27）

高度血液学毒性：方案A和B分别为27.9%（12/43）和4.8%（1/21）

无进展间期（PFI）：方案A和B二线治疗无差异

周疗方案（方案B）严重血液学毒性较低

三线以上治疗有效率极低（建议二线使用）

JChemother.Apr19:1-6.[Epubaheadofprint]

Analysisoftwotopotecantreatmentschedulesinpatientswithrecurrentovariancancer.

BruchimI,Ben-HarimZ,PiuraE,HaranG,FishmanA.

MeirMedicalCenter,KfarSaba,Israel.

SacklerSchoolofMedicine,TelAvivUniversity,TelAviv,Israel.

Twotopotecantreatmentschedulesinpatientswithrecurrentepithelialovariancancerwereevaluated.ProtocolA(21days)was1.5mg/m2/daytopotecanondays1through5ofa21-daycycle;ProtocolB(weekly)4mg/m2ondays1,8,and15ofa28-daycycle.Efficacywasdeterminedbyclinicalexam,CTscan,andCAlevels.Forty-threepatientsonProtocolAand21onProtocolBwereevaluated.Assecond-linetreatment,ProtocolAresponsewas9/20(45%).ResponsetoProtocolBwas4/17(23.5%;NS).Asthirdlineormore,theresponseonProtocolsAandBtogetherwasonly3/27(11%).High-gradehaematologicaltoxicitywasreportedin12/43(27.9%)onProtocolAand1/21(4.8%)onProtocolB(p=0.04).Therewasnodifferenceinprogression-free-intervalsbetweenschedulesinsecond-linetreatment.Theweeklyprotocolhadlowerseverehaematologicaltoxicity.Clinicalresponseinthirdlineormorewasverylow.

KEYWORDS:Chemotherapy;Epithelialovariancancer;Topotecan

PMID:

DOI:10./X..